Thiamine-Responsive Megaloblastic Anemia Syndrome (TRMA / Rogers Syndrome): Comprehensive Research Report

1. Disease Information

Overview. Thiamine-responsive megaloblastic anemia syndrome (TRMA), also known as Rogers syndrome, is a rare autosomal recessive metabolic disorder caused by biallelic loss-of-function variants in SLC19A2, which encodes the high-affinity thiamine (vitamin B1) transporter THTR-1. The disease is defined by a classic clinical triad — megaloblastic anemia, non-type 1 (non-autoimmune) diabetes mellitus, and progressive sensorineural hearing loss — with onset typically between infancy and adolescence. It is distinguished from other congenital anemias by its dramatic, though incomplete, responsiveness to pharmacologic (supraphysiologic) doses of oral thiamine (GeneReviews, NBK1282).

Key identifiers: - OMIM: #249270 (Thiamine-Responsive Megaloblastic Anemia Syndrome; also called Thiamine Metabolism Dysfunction Syndrome 1, THMD1) (OMIM:249270) - Orphanet: ORPHA:49827 (Orphanet) - MONDO: MONDO:0009575 - ICD-10-CM: D53.1 (Other megaloblastic anemias, not elsewhere classified) — TRMA has no dedicated ICD-10 code and is billed under this broader category - MedGen concept: C0342287 — "Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness" (NCBI MedGen) - Gene: SLC19A2 (HGNC:11021), chromosome 1q24.2 (also cited as 1q23.3 in older sources)

Synonyms: Rogers syndrome; TRMA syndrome; Thiamine-responsive anemia with diabetes mellitus and sensorineural deafness; Roger syndrome.

Data provenance. Nearly all published knowledge on TRMA derives from aggregated case reports and small case series (individual-patient/family-level data) rather than large disease-level registries, reflecting the disorder's extreme rarity — GeneReviews estimates "more than 183 individuals from approximately 138 families" reported worldwide (GeneReviews, NBK1282), and MedlinePlus similarly cites "approximately 200 cases documented in medical literature" (MedlinePlus Genetics). A newly reported founder-mutation cluster in the Ingush population (see §9) is the first population/cohort-level epidemiologic dataset for the disease (PMID:42511616).

2. Etiology

Disease causal factor: monogenic, autosomal recessive. TRMA is caused exclusively by biallelic (homozygous or compound heterozygous) pathogenic variants in SLC19A2. There is no known environmental, infectious, or purely mechanistic (non-genetic) cause; dietary thiamine deficiency produces classical beriberi/Wernicke pathology, not TRMA, because TRMA arises from a cellular transport defect rather than systemic vitamin insufficiency.

Genetic risk factors: - Biallelic SLC19A2 pathogenic variants — the sole causal factor. - Consanguinity is a major risk factor for expression of this rare recessive disease; GeneReviews notes it is "exceedingly rare outside of consanguineous families or isolated populations," with reported kindreds from Israeli Arab, Lebanese, Alaskan Native/Russian, Brazilian, Japanese, Omani, Tunisian, Italian, Iranian, Indian, Pakistani, Kashmiri, Kurdish, northern European, and African American populations (GeneReviews, NBK1282). - Founder effects / isolated populations: A newly characterized SLC19A2 c.1223+1G>A canonical splice-site founder variant is endemic in the Ingush population of the North Caucasus, with a heterozygous carrier frequency of 2.7% (≈1/36) in a reference cohort of 328 unrelated adults, sharing a 2.3 Mb ATP1B1–FMO2 founder haplotype on chromosome 1 (PMID:42511616). - No modifier genes have been identified; GeneReviews explicitly states no genotype–phenotype correlation exists — clinical severity and which triad features manifest vary unpredictably even within families carrying the same variant (GeneReviews, NBK1282).

Environmental/risk-modifying factors: None established as independent disease-causing factors. However, dietary thiamine status modulates phenotype severity in model systems — in Slc19a2-null mice, diabetes and cochlear pathology are diet-dependent, emerging specifically on a thiamine-free diet and resolving/normalizing on thiamine repletion or a thiamine-replete diet (PMID:12393806; PMID:16642288), suggesting maternal/dietary thiamine intake could plausibly modulate age of clinical onset in humans, though this is not directly demonstrated in patients.

Protective factors: Pharmacologic-dose thiamine supplementation is the only known modifier that ameliorates (though does not cure) the phenotype — it is protective against progression of anemia, thrombocytopenia, and (partially) diabetes onset, but does not prevent or reverse hearing loss (see §12). No protective genetic variants have been described; a residual second thiamine transporter, THTR-2 (encoded by the paralog SLC19A3), provides partial intestinal compensation but has minimal expression in the tissues driving TRMA pathology (bone marrow, pancreatic β-cells, cochlea), so it does not meaningfully rescue phenotype (GeneReviews, NBK1282).

Gene-environment interaction: The core gene-environment interaction is the treatment mechanism itself: loss of the high-affinity, saturable THTR-1 transport pathway is functionally bypassed by supraphysiologic extracellular thiamine concentrations that drive passive/low-affinity diffusion into cells, restoring intracellular thiamine pyrophosphate (TPP) levels sufficient for thiamine-dependent enzymes (MedlinePlus Genetics).

3. Phenotypes

TRMA phenotypes span hematologic, endocrine, otologic, ophthalmologic, cardiovascular, and neurologic domains. Frequencies below are as reported in GeneReviews' pooled case-series data (GeneReviews, NBK1282).

Quality-of-life impact: No disease-specific EQ-5D/SF-36 data were located. Qualitatively, the irreversible progressive sensorineural hearing loss is the most functionally durable burden (unlike anemia, unresponsive to thiamine), often requiring hearing aids or cochlear implantation for rehabilitation — one case report specifically documents "successful hearing rehabilitation by cochlear implantation" in a TRMA patient (ScienceDirect case report). Insulin-dependent diabetes and its complications, plus the cardiovascular/neurologic complication burden in ~20–40% of patients, are the other major chronic quality-of-life determinants (GeneReviews, NBK1282).

Diagnostic mimicry note: Because bone marrow shows dysplastic hematopoiesis with megaloblasts and ringed sideroblasts, TRMA is noted to be easily mistaken for acquired myelodysplastic syndrome (MDS) — a recent case report is explicitly titled "Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm" (Karger, Acta Haematologica), underscoring the importance of distinguishing the two given their divergent prognosis and management.

4. Genetic/Molecular Information

Causal gene: SLC19A2 (Solute Carrier Family 19 Member 2), HGNC:11021, located on chromosome 1q24.2, spanning 6 exons. It encodes Thiamine Transporter 1 (THTR-1/ThTr1), a 497-amino-acid protein with 12 predicted transmembrane domains, structurally homologous to the reduced folate carrier family (GeneCards SLC19A2; PMID:33649974). THTR-1 is the sole thiamine transporter expressed in bone marrow, cochlear tissue, and pancreatic β-cells, which accounts for the tissue-specificity of the clinical triad — a second, paralogous transporter (THTR-2, encoded by SLC19A3) is more broadly/intestinally expressed but does not substitute in these tissues (PMID:33649974).

Discovery: SLC19A2 was identified by positional cloning in 1999 as the gene mutated in TRMA-segregating families, initially reported by two independent groups; Labay et al. (Nature Genetics, 1999) reported "Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness" (PMID:10391221; Nature Genetics ng0799_300).

Pathogenic variant spectrum: A systematic analysis of reported variants found frameshift variants (31%), nonsense variants (24%), and large deletions (3%) — together accounting for 55% of all reported pathogenic alleles and predicted to cause premature termination and protein truncation. Truncating variants localize predominantly to transmembrane domains (46.3%), cytoplasmic domains (34.1%), and extracellular domains (19.5%); missense variants localize to transmembrane domains (59.3%), extracellular domains (29.6%), and cytoplasmic domains (11.1%) (PMID:33649974). Whole-gene deletions/duplications are rare (reported in only 2 families) (GeneReviews, NBK1282). A recently reported complex example combines a heterozygous missense variant (c.1001G>A, p.Gly334Asp) with a 3.4 Mb structural inversion of exons 2–6 on the second allele, producing a functionally null allele — illustrating that structural variant analysis may be needed when standard sequencing finds only one pathogenic allele.

Variant classification/interpretation: Sequence analysis (Sanger or NGS-based) detects >99% of pathogenic variants (missense, nonsense, splice-site, small indels); gene-targeted deletion/duplication analysis (e.g., MLPA, CMA) is recommended as a reflex test when only one or no variant is found by sequencing (GeneReviews, NBK1282). ACMG/AMP-based ClinVar classifications exist for the reported alleles but a curated aggregate summary was not directly retrievable in this search; GeneCards/ClinVar and locus-specific databases should be consulted for the current pathogenic/likely-pathogenic variant list.

Population/allele frequency: SLC19A2 pathogenic alleles are rare in gnomAD generally — most pathogenic alleles are absent or present at frequencies below 0.00001 — but show strong founder enrichment in specific populations. The missense variant p.(Gly334Asp) has one of the higher reported gnomAD allele frequencies (~0.00002). The Ingush founder splice variant c.1223+1G>A reaches a striking 2.7% heterozygous carrier frequency (≈1/36) in that population due to a shared 2.3 Mb founder haplotype (PMID:42511616).

Zygosity/origin: All reported pathogenic variants are germline; TRMA has no described somatic form. Both homozygous and compound heterozygous genotypes are reported. A case report specifically documents maternal uniparental isodisomy as a mechanism producing homozygosity for a single maternally inherited SLC19A2 pathogenic variant, despite only one parent being a carrier — an important non-classical mechanism to consider in apparent "homozygosity" without biparental transmission (PMC8017196).

Functional consequences: Loss-of-function is the uniform mechanism — pathogenic missense variants in transmembrane domains cause aberrant protein folding/mislocalization (disrupted trafficking to the plasma membrane) with near-complete loss of transport function, while nonsense/frameshift variants produce truncated, non-functional or absent protein (PMID:33649974; GeneReviews, NBK1282). There is no described gain-of-function, dominant-negative, or hypermorphic mechanism.

Modifier genes: None established; disease expression is unpredictable across genotypically similar/identical patients (no genotype–phenotype correlation) (GeneReviews, NBK1282).

Epigenetic information / chromosomal abnormalities: No epigenetic mechanism or recurrent chromosomal aneuploidy/translocation has been described for TRMA; disease is driven by point/small-indel/structural loss-of-function variants confined to the SLC19A2 locus.

5. Environmental Information

TRMA is a purely monogenic disorder with no established infectious, toxic, or occupational-exposure etiology. The principal "environmental" lever is dietary/therapeutic thiamine, which is not a disease cause but the disease's specific pharmacologic countermeasure (see §2, §12). No lifestyle risk factor (smoking, alcohol, exercise) has been linked to TRMA onset or severity in the literature reviewed. No infectious trigger is reported. Consanguinity, discussed above, functions as a population-genetic risk factor rather than a true environmental exposure.

6. Mechanism / Pathophysiology

Causal chain overview: Biallelic SLC19A2 loss-of-function → absence of the high-affinity, saturable thiamine transport component at the plasma membrane of bone marrow precursors, pancreatic β-cells, and cochlear cells → low intracellular free thiamine and thiamine pyrophosphate (TPP) concentration in these tissues (despite normal serum thiamine) → impaired function of TPP-dependent enzymes, most notably transketolase in the non-oxidative branch of the pentose phosphate pathway → defective ribose synthesis for nucleic acid (RNA/DNA) production → impaired DNA synthesis and cell-cycle progression in rapidly dividing hematopoietic precursors, producing megaloblastic dysplastic hematopoiesis; and cellular stress/apoptosis in pancreatic β-cells and cochlear hair cells → clinical triad of megaloblastic anemia, diabetes mellitus, and sensorineural deafness (GeneReviews, NBK1282; Blood, PMID search "Defective RNA ribose synthesis").

Molecular pathway / biochemical abnormality: Thiamine pyrophosphate (TPP), the active cofactor form of thiamine, is required by transketolase (pentose phosphate pathway, non-oxidative branch), pyruvate dehydrogenase, and α-ketoglutarate dehydrogenase (TCA cycle). In TRMA fibroblasts, the fractional synthetic rate of ribose is reduced, and the balance of ribose synthesis shifts away from the preferred transketolase/transaldolase-dependent non-oxidative branch toward the oxidative pentose pathway branch, which cannot fully compensate — this reduced nucleic-acid ribose production is proposed as the proximate biochemical lesion driving cell-cycle arrest/apoptosis in bone marrow cells ("Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA)," Blood — bloodjournal.org). An earlier syndrome overlapping TRMA's triad was also linked to deficient α-ketoglutarate dehydrogenase activity, a second TPP-dependent enzyme (PMID:4045602), consistent with broad TPP-cofactor insufficiency as the shared downstream lesion.

Cell type/tissue involvement: - Hematopoietic precursors (bone marrow): dysplastic megaloblastic erythropoiesis with numerous megaloblasts and iron-laden mitochondria (ringed sideroblasts); thrombocytopenia and neutropenia in a subset, likely reflecting shared TPP-dependence across marrow lineages. - Pancreatic β-cells: THTR-1 is "the only transporter of thiamine into pancreatic β-cells," and its deficiency "leads to cell apoptosis and organ failure" (i.e., β-cell loss driving non-autoimmune, non-type-1 diabetes) — search summary from thiamine/diabetes mechanistic review (PMC8505293, "Thiamine and diabetes: back to the future?"). - Cochlear hair cells: In the Slc19a2-null mouse model on a low-thiamine diet, histology shows selective inner hair cell loss occurring within 1–2 weeks of thiamine restriction, with progressively greater inner-than-outer hair cell loss on longer challenge, producing an auditory neuropathy-like phenotype; auditory brainstem response (ABR) thresholds are markedly elevated on a thiamine-free diet but normal on a thiamine-replete diet (PMID:16642288). This maps the human "unclear basis" hearing loss to selective inner hair cell vulnerability.

Molecular profiling / advanced technologies: No transcriptomic, proteomic, metabolomic, or single-cell/spatial datasets specific to human TRMA tissue were identified in this search; mechanistic insight instead derives from patient fibroblast biochemistry (ribose synthesis assays) and the Slc19a2-knockout mouse model.

GO/CL term suggestions: - Molecular function: GO:0034219 (carbohydrate transmembrane transport) / more specifically thiamine transmembrane transporter activity - Biological process: GO:0006772 (thiamine metabolic process); pentose-phosphate shunt, non-oxidative branch (GO:0009052) - Cell types: CL:0000542 (lymphocyte) not relevant; relevant CL terms include CL:0000038 (erythroid progendaughter/erythroid progenitor cell), CL:0000169 (type B pancreatic cell), CL:0000598 (cochlear inner hair cell)

7. Anatomical Structures Affected

Organ level: - Primary: Bone marrow (hematopoietic system), pancreas (endocrine, islets of Langerhans), inner ear/cochlea (auditory system). - Secondary: Eye (optic nerve, retina), heart (conduction system, septa), central and peripheral nervous system, vasculature (stroke risk). - Body systems involved: Hematologic, endocrine, auditory/vestibular, ophthalmologic, cardiovascular, neurologic.

Tissue and cell level: - Bone marrow erythroid, myeloid, and megakaryocytic precursors (dysplastic, megaloblastic change; ringed sideroblasts on iron stain). - Pancreatic islet β-cells (CL:0000169). - Cochlear inner hair cells (CL:0000598), with relative sparing of outer hair cells in the mouse model, suggesting a similar pattern may occur in humans (PMID:16642288). - Retina/optic nerve (cone-rod dystrophy, optic atrophy). - Cardiac conduction tissue and myocardium (atrial standstill, arrhythmia, high-output failure).

Subcellular level: Mitochondria are directly implicated — the megaloblastic marrow shows iron-filled mitochondria (ringed sideroblasts), and TPP-dependent mitochondrial enzymes (pyruvate dehydrogenase, α-ketoglutarate dehydrogenase) are plausible downstream targets of thiamine deficiency alongside the cytosolic pentose phosphate pathway enzyme transketolase. GO Cellular Component terms of interest: GO:0005739 (mitochondrion), GO:0005829 (cytosol, site of transketolase activity), GO:0005886 (plasma membrane, site of THTR-1 localization).

Localization / laterality: Sensorineural hearing loss and cochlear involvement are typically bilateral; cardiac and ophthalmologic findings are systemic/bilateral in nature rather than lateralized.

UBERON term suggestions: UBERON:0002371 (bone marrow), UBERON:0001264 (pancreas), UBERON:0001846 (cochlea), UBERON:0000970 (eye), UBERON:0000948 (heart).

8. Temporal Development

Onset: TRMA onset spans infancy through adolescence, with the earliest anemia findings in the first year of life and latest reported presentations in the teenage years. All three triad features are frequently not present simultaneously at initial presentation — patients often present with one or two features first, with the remaining feature(s) emerging over subsequent years (GeneReviews, NBK1282). Hearing loss is often detected early, in toddlers, and may be congenital/prelingual in some patients.

Progression: - Megaloblastic anemia: corrects with pharmacologic thiamine but red cells remain macrocytic; anemia recurs promptly if thiamine is withdrawn — i.e., a chronic, treatment-dependent (not curative) course. - Sensorineural hearing loss: progressive and irreversible; thiamine treatment does not halt or reverse it, distinguishing its course sharply from the hematologic component. - Diabetes mellitus: progressive; while thiamine may reduce insulin requirement and delay onset in some individuals, most patients eventually require insulin therapy; diabetic ketoacidosis occurs in ~15%. - Cardiovascular/neurologic/ophthalmologic complications: variable, sometimes severe (sudden death, stroke, atrial standstill), and thiamine's efficacy against these is not established.

Disease course pattern: Chronic and lifelong; not self-limited. No spontaneous remission is described. The disease requires indefinite pharmacologic thiamine dosing — GeneReviews states anemia recurs "if treatment is withdrawn," underscoring that TRMA is managed, not cured.

Critical periods: Early diagnosis and thiamine initiation is repeatedly emphasized as critical — an Italian case series is explicitly titled around "the importance of early diagnosis and treatment" (PMC10691017), consistent with the concept that early thiamine repletion may forestall or blunt onset of diabetes and preserve residual hearing, even though it cannot reverse established sensorineural damage.

9. Inheritance and Population

Epidemiology: TRMA is exceedingly rare, with formal prevalence/incidence statistics unknown; the literature has historically reported "less than 80 cases worldwide" in earlier summaries and up to ~200 cases / 138 families in more recent GeneReviews/MedlinePlus tallies (both figures reflect case-series accumulation rather than population-based ascertainment) (GeneReviews, NBK1282; MedlinePlus Genetics).

Inheritance pattern: Autosomal recessive. At conception, each sibling of an affected individual has a 25% chance of being affected, 50% chance of being an asymptomatic carrier, and 25% chance of being unaffected/non-carrier (GeneReviews, NBK1282). Heterozygous carriers are clinically asymptomatic.

Penetrance/expressivity: Effectively complete penetrance for biallelic pathogenic genotypes (disease manifests), but markedly variable expressivity — which triad components appear, their severity, and age of onset differ unpredictably between and even within families, with no genotype–phenotype correlation established (GeneReviews, NBK1282).

Genetic anticipation: Not described; TRMA is not a repeat-expansion disorder.

Germline mosaicism / uniparental disomy: A documented mechanism of apparent "homozygosity" without both parents being carriers is maternal uniparental isodisomy of chromosome 1, producing two identical maternal copies of a single pathogenic SLC19A2 allele (PMC8017196) — an important consideration for genetic counseling when only one parent tests as a carrier.

Founder effects / consanguinity: TRMA is strongly enriched in consanguineous unions and in geographically/ethnically isolated populations. The best-documented founder effect is the Ingush population of the North Caucasus (Russia), where the canonical splice variant SLC19A2 c.1223+1G>A reaches a heterozygous carrier frequency of 2.7% (≈1/36) in a reference cohort of 328 unrelated adults, tracing to a shared 2.3 Mb ATP1B1–FMO2 founder haplotype; this study newly identifies Ingushetia as a TRMA-endemic region and recommends targeted screening and early thiamine therapy for macrocytic anemia/diabetes of unclear origin in that population — notably, all identified patients became transfusion-independent on high-dose thiamine therapy (PMID:42511616). Other reported founder/cluster populations include Israeli Arab, Lebanese, Alaskan Native/ethnic Russian, Brazilian, Japanese, Omani, Tunisian, Italian, Iranian, Indian, Pakistani, Kashmiri (in Great Britain), and Kurdish kindreds (GeneReviews, NBK1282).

Carrier frequency: Population-wide carrier frequency is presumably very low outside founder populations (consistent with gnomAD data showing most pathogenic SLC19A2 alleles at allele frequency <0.00001), but reaches 2.7% in the Ingush founder population specifically (PMID:42511616).

Sex ratio / geographic distribution: No sex predilection is reported (consistent with autosomal inheritance). Geographic distribution is scattered/sporadic worldwide, reflecting the disorder's dependence on consanguinity/founder effects rather than a specific endemic geography, with the Ingush cluster as a notable exception.

10. Diagnostics

Clinical/biochemical diagnostic criteria: Per GeneReviews, the diagnosis of TRMA is established in a proband with megaloblastic anemia with normal vitamin B12/folic acid levels, with or without diabetes or hearing loss, who shows a response to oral thiamine (GeneReviews, NBK1282). This clinical/biochemical criterion is typically confirmed molecularly.

Laboratory tests: - CBC with elevated MCV (macrocytosis), low hemoglobin. - Reticulocyte count (monitored for treatment response). - Bone marrow aspirate/biopsy: megaloblastic, dysplastic hematopoiesis with ringed sideroblasts (iron stain). - Normal serum vitamin B12 and folate (key distinguishing feature from nutritional megaloblastic anemias). - Fasting glucose, oral glucose tolerance test, urinalysis for glucose intolerance/diabetes screening.

Genetic testing: - First-line: Sequence analysis of SLC19A2 (Sanger or targeted NGS), which detects >99% of pathogenic variants including small indels, missense, nonsense, and splice-site variants. - Reflex testing: Gene-targeted deletion/duplication analysis (e.g., MLPA, chromosomal microarray) when only one or no variant is identified by sequencing — relevant given rare reported whole-gene deletions/duplications and structural variants (e.g., the exon 2–6 inversion case). - Broader testing: Multigene panels for congenital sideroblastic/megaloblastic anemia or syndromic deafness-diabetes, or comprehensive genomic testing (exome/genome sequencing), particularly useful when the clinical presentation is atypical or incomplete (GeneReviews, NBK1282). - Uniparental disomy testing may be informative in cases of apparent unexplained homozygosity (PMC8017196).

Imaging/other: No disease-specific imaging modality; echocardiography is indicated given the 20–30% cardiovascular involvement rate (structural defects, arrhythmia, atrial standstill); audiometry/ABR for hearing assessment; ophthalmologic exam (fundoscopy, possibly electroretinography) for retinal/optic nerve involvement.

Differential diagnosis (from GeneReviews):

Screening: No population newborn-screening program exists for TRMA given its extreme rarity, though the Ingush founder-population study explicitly recommends targeted carrier/diagnostic screening for SLC19A2 c.1223+1G>A in that specific population given macrocytic anemia or diabetes of unclear origin (PMID:42511616).

11. Outcome/Prognosis

Survival/mortality: No systematic survival statistics (5-year/10-year survival, life expectancy) were located in the literature searched; sudden cardiac death is reported as a rare but real complication, and the disease's cardiovascular (20–30%) and neurologic (20–40%, including stroke) complication burden implies meaningful excess morbidity/mortality risk relative to the general population, though quantified rates were not found.

Morbidity/function: The dominant chronic morbidity driver is irreversible progressive sensorineural hearing loss, which persists regardless of thiamine treatment and is managed with hearing aids or cochlear implantation. Insulin-dependent diabetes contributes long-term micro/macrovascular risk typical of any chronic diabetes. The 20–40% rate of neurologic complications (developmental delay, intellectual disability, epilepsy, stroke) and 20–30% rate of cardiovascular complications (arrhythmia, congenital heart defects, high-output failure) represent additional major sources of long-term disability.

Recovery potential / treatment impact: With thiamine treatment, hematologic parameters (anemia, thrombocytopenia, neutropenia) reliably improve, and some patients — as in the Ingush cohort — become fully transfusion-independent on high-dose thiamine therapy (PMID:42511616). Diabetes may be delayed in onset or require reduced insulin dosing with thiamine, but is not reliably reversed. Hearing loss, once established, does not recover with thiamine.

Prognostic factors: Early diagnosis and early initiation of thiamine therapy is repeatedly emphasized in the literature as the single most actionable prognostic factor, given its role in mitigating hematologic disease and potentially delaying diabetes onset, even though it cannot rescue hearing (PMC10691017). No molecular biomarker for prognosis (beyond genotype, which does not correlate with severity) has been established.

12. Treatment

Primary pharmacotherapy: Lifelong oral thiamine (vitamin B1) at pharmacologic doses of 50–100 mg/day (occasionally reported up to 25–100 mg/day in at-risk relatives pending genetic confirmation), regardless of patient age, is the cornerstone of TRMA management. GeneReviews notes no additional clinical benefit is observed above 150 mg/day. Thiamine "invariably improves hematologic findings" but must be continued indefinitely, as anemia recurs upon discontinuation (GeneReviews, NBK1282). - NCIT suggestion: NCIT:C15986 (Pharmacotherapy), with therapeutic_agent bound to thiamine (CHEBI, if available) — vitamin/nutrient supplementation therapy.

Manifestation-specific treatment:

Advanced therapeutics: No gene therapy, cell therapy, RNA-based therapy, or targeted molecular therapy has been developed or trialed for TRMA specifically — the disease is managed entirely through cofactor-bypass pharmacotherapy (high-dose thiamine) and manifestation-directed supportive/specialist care. No disease-specific registered clinical trials (ClinicalTrials.gov, NCT identifiers) were identified for TRMA in this search, consistent with its ultra-rare status; management guidance derives from case-series experience rather than randomized trials.

Treatment response/outcomes: Response to thiamine is the diagnostic hallmark itself (see §10) — reticulocytosis and hemoglobin normalization are expected within weeks of thiamine initiation. Diabetes response is more variable: thiamine "may reduce insulin requirement and delay onset of diabetes in some individuals" but is not curative. No systematic adverse-event data for high-dose thiamine in TRMA were found; oral thiamine is generally very well tolerated even at pharmacologic doses.

Pregnancy management: GeneReviews specifically recommends good diabetic control prior to and during pregnancy in affected women.

Genetic counseling / at-risk relative management: GeneReviews recommends empiric thiamine supplementation (25–100 mg/day, compared with the US RDA of ~1.5 mg/day) for at-risk siblings as early as possible, pending determination of their genetic/carrier status, given the low harm profile of thiamine and the benefit of early treatment if affected (GeneReviews, NBK1282).

13. Prevention

Primary prevention: Because TRMA is a fully penetrant monogenic recessive disorder, primary prevention is achieved through genetic counseling and carrier screening in at-risk families/populations (particularly consanguineous families and founder populations such as the Ingush cluster), plus prenatal and preimplantation genetic testing once the family's pathogenic variant(s) are identified (GeneReviews, NBK1282; PMID:42511616). There is no vaccine or environmental-exposure-avoidance strategy relevant to this genetic disease.

Secondary prevention (early detection): Because thiamine treatment cannot reverse established hearing loss but can prevent/attenuate anemia and delay diabetes, early diagnosis via clinical suspicion (megaloblastic anemia with normal B12/folate, especially with diabetes or deafness) followed by prompt genetic confirmation and thiamine initiation functions as the operative secondary-prevention strategy — repeatedly emphasized across case reports as the modifiable determinant of outcome (PMC10691017; PMID:42511616). Empiric thiamine supplementation of at-risk siblings pending genetic testing is a specific, actionable secondary-prevention measure per GeneReviews.

Tertiary prevention: Lifelong surveillance (see below) and manifestation-specific specialist management (audiology, endocrinology, cardiology, ophthalmology, neurology) aim to detect and manage complications before they become severe.

Surveillance schedule (GeneReviews): At least annual evaluation is recommended, including: - Hematologic tests (CBC, reticulocyte count) to monitor thiamine treatment efficacy. - Glucose intolerance assessment (fasting glucose, OGTT, urinalysis). - Hearing, ophthalmologic, cardiac, and neurologic evaluations. - Assessment for manifestations of poor glycemic control (GeneReviews, NBK1282).

Genetic counseling: Standard autosomal recessive counseling applies (25% recurrence risk per pregnancy for carrier parents); population-specific counseling and targeted variant screening is now specifically recommended for the Ingush population given the newly characterized founder mutation (PMID:42511616).

14. Other Species / Natural Disease

No naturally occurring veterinary or wildlife disease analogous to TRMA (i.e., spontaneous SLC19A2-deficiency disease in companion animals or livestock) was identified in this search — this appears to be an area with no OMIA (Online Mendelian Inheritance in Animals) entry located, and no veterinary case series were found. The disease as studied in other species is confined to engineered/induced laboratory models (§15) rather than naturally occurring animal disease.

Orthology: SLC19A2 shows conserved orthology across human, mouse, rat, and zebrafish, indicating cross-species conservation of thiamine transporter biology, though this has not translated into documented spontaneous natural disease reports in non-human species in the literature surveyed.

15. Model Organisms

Mouse (Mus musculus) — the principal TRMA model: - Model: Slc19a2-null (targeted knockout) mouse, generated via homologous recombination/gene-trap disruption in embryonic stem cells (MGI:1928761) (PMID:12393806; MGI Slc19a2). - Phenotype recapitulation: - Erythrocytes from Slc19a2⁻/⁻ mice lack the high-affinity component of thiamine transport, mirroring the human cellular defect. - On a thiamin-free diet, Slc19a2⁻/⁻ mice develop diabetes mellitus with reduced insulin secretion and enhanced peripheral insulin sensitivity; this diabetes resolves after ~6 weeks of thiamin repletion, directly modeling the human treatment-responsiveness (PMID:12393806). - Auditory brainstem response (ABR) thresholds are markedly elevated in Slc19a2⁻/⁻ mice on a thiamin-free diet but remain normal in wild-type mice on the same diet and in thiamin-fed knockouts — demonstrating diet-dependence of the hearing phenotype. - Cochlear histology reveals selective inner hair cell loss after 1–2 weeks of low-thiamine challenge, with progressively greater inner-versus-outer hair cell loss over longer challenge periods, producing an auditory neuropathy phenotype; cochlear function is normal in mutants maintained on a high-thiamine diet (PMID:16642288). - Bone marrow analysis in this model shows evidence for defective deoxyribose and heme synthesis, mechanistically linking the transporter defect to impaired hematopoiesis (ASH Blood abstract, "Role of Defective High-Affinity Thiamine Transporter slc19a2 in Marrow..."). - Model limitations: The mouse phenotype is strongly diet-dependent (requiring a thiamin-free diet to unmask diabetes/deafness), whereas human patients develop disease despite normal dietary thiamine intake — reflecting a difference in baseline thiamine reserve/requirement or transporter redundancy between species that should be considered when extrapolating findings. This is a case where the model requires an added environmental manipulation (dietary thiamine restriction) to recapitulate a phenotype that arises spontaneously from genotype alone in humans — i.e., a PARTIALLY_RECAPITULATES relationship, gated by diet, rather than full spontaneous recapitulation. - Research applications: This model has been the primary tool for establishing the diet-thiamine-dependence of the diabetes and cochlear phenotypes and for identifying selective inner hair cell vulnerability as the auditory pathology substrate.

Human patient-derived cellular models: - Patient dermal fibroblasts and erythrocytes have been used directly (not as engineered lines) to demonstrate loss of high-affinity thiamine uptake and to quantify defective RNA ribose synthesis via the transketolase-dependent non-oxidative pentose phosphate pathway branch, providing the primary human cellular mechanistic evidence base (Blood, "Defective RNA ribose synthesis in fibroblasts from patients with TRMA"; JCI PDF, "Defective high-affinity thiamine transporter leads to cell...").

iPSC / zebrafish / Drosophila models: No TRMA-specific induced pluripotent stem cell line, zebrafish model, or Drosophila model was identified in this search, despite conserved SLC19A2 orthology in zebrafish making such a model theoretically feasible. (For comparison/contrast, iPSC models exist for the related paralog disease, SLC19A3-associated Biotin-Thiamine-Responsive Basal Ganglia Disease — e.g., KAIMRCi004-A/B lines — but these model a genetically and phenotypically distinct disorder, not TRMA itself.) This represents an apparent gap in available model-system resources for TRMA specifically.

Resources: MGI:1928761 (mouse Slc19a2 gene page, with knockout allele information) is the primary curated animal-model database entry identified (MGI).

Summary Table of Key Ontology Term Suggestions

Sources

• Thiamine-Responsive Megaloblastic Anemia Syndrome — GeneReviews®, NCBI Bookshelf (NBK1282)
• OMIM #249270 — Thiamine-Responsive Megaloblastic Anemia Syndrome
• Orphanet: Thiamine-responsive megaloblastic anemia syndrome (ORPHA:49827)
• MedlinePlus Genetics: Thiamine-responsive megaloblastic anemia syndrome
• NCBI MedGen C0342287
• GARD (NIH) — Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness
• Labay V, et al. "Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness." Nat Genet. 1999. PMID:10391221 / Nature Genetics ng0799_300
• Oishi K, et al. "Targeted disruption of Slc19a2, the gene encoding the high-affinity thiamin transporter Thtr-1, causes diabetes mellitus, sensorineural deafness and megaloblastosis in mice." Hum Mol Genet. 2002. PMID:12393806
• "Deletion of SLC19A2, the High Affinity Thiamine Transporter, Causes Selective Inner Hair Cell Loss and an Auditory Neuropathy Phenotype." JARO. PMID:16642288
• "The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2." PMID:33649974
• "An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation" (Ingush population). PMID:42511616
• "Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA)." Blood. bloodjournal.org
• "Diabetes mellitus, thiamine-dependent megaloblastic anemia, and sensorineural deafness associated with deficient alpha-ketoglutarate dehydrogenase activity." PMID:4045602
• "Case Report: Genetic and Clinical Features of Maternal Uniparental Isodisomy-Induced Thiamine-Responsive Megaloblastic Anemia Syndrome." PMC8017196
• "An Italian case series' description of thiamine responsive megaloblastic anemia syndrome: importance of early diagnosis and treatment." PMC10691017
• "Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm." Acta Haematologica. Karger
• "Cardiac Manifestations in Thiamine-Responsive Megaloblastic Anemia Syndrome." Pediatric Cardiology. SpringerLink
• "Thiamine-responsive megaloblastic anemia syndrome with atrial standstill: a case report." PMID:21285901
• "Thiamine responsive megaloblastic Anemia and deafness: A rare case of Roger's syndrome with successful hearing rehabilitation by cochlear implantation." ScienceDirect
• SLC19A2 gene — GeneCards (SLC19A2 protein structure). GeneCards
• MGI:1928761 — Slc19a2 Mouse Gene Detail. Jackson Laboratory MGI
• "[Thiamine-responsive megaloblastic anemia or Rogers syndrome: A literature review]." PMID:30031565

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMC:PMC10691017 (abstract only): "the importance of early diagnosis and treatment"
• closest text in source: "In Cases 2 and 3, follow-up showed no blindness, unlike Case 4, in which treatment was started for megaloblastic anemia at age 7 but was increased to high doses only at age 25, when the genetic diagnosis of TRMA was performed"